MAYO CLINIC
Mayo Medical Laboratories

TEST STATUS-OBSOLETE
MML-FLORIDA
NOTIFICATION DATE: March 12, 2018
EFFECTIVE DATE: April 12, 2018

EPSTEIN-BARR VIRUS (EBV), MOLECULAR DETECTION, QUANTITATIVE PCR, BLOOD
Test ID: QEBV

EXPLANATION: This test will become obsolete on the effective date and will be replaced with test code: EBVQU- Epstein-Barr Virus DNA Detection and Quantification, Plasma.

Please note the following major changes:

CURRENT TEST **QEBV**	
Sample type	Whole blood
Reporting unit	Copies/mL
Reportable range	Not applicable

NEW TEST **EBVQU**	
Sample type	Plasma
Reporting unit	International Units (IU)/mL
Reportable range	100 – 5,000,000 IU/mL

RECOMMENDED ALTERNATIVE TEST:

EPSTEIN-BARR VIRUS DNA DETECTION AND QUANTIFICATION, PLASMA
Test ID: EBVQU

USEFUL FOR:
- Diagnosis of posttransplant lymphoproliferative disorders (PTLD), especially in EBV-seronegative organ transplant recipients receiving antilymphocyte globulin for induction immunosuppression and OKT-3 treatment for early organ rejection
- Monitoring progression of EBV-associated PTLD in organ transplant recipients

METHOD: Real-Time Polymerase Chain Reaction (PCR) Followed by Minor Groove-Binding (MGB) Probe Hybridization

REFERENCE VALUES: Undetected

SPECIMEN REQUIREMENTS:
Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1.5 mL
Collection Instructions:
1. Centrifuge blood collection tube per collection tube manufacturer's instructions.
2. Pour off plasma into aliquot tube.
Minimum Volume: 0.8 mL

SPECIMEN STABILITY INFORMATION:

Specimen Type	Temperature	Time
Plasma EDTA	Frozen (preferred)	30 days
	Refrigerated	7 days

CAUTIONS:
Serial determination of plasma specimens from organ transplant recipients may be necessary to monitor increasing (risk of development of posttransplant lymphoproliferative disorders: PTLD) or decreasing (treatment efficacy) levels of Epstein-Barr virus (EBV) DNA.

Nonsymptomatic EBV viremia or viral shedding may occur occasionally in healthy individuals. Therefore, this test should be used only for patients with a clinical history and symptoms consistent with EBV infection, and must be interpreted in the context of patient's clinical history, signs and symptoms. This test should not be used to screen asymptomatic patients.

Only plasma specimens are acceptable for testing with this assay, and lipemic plasma specimens may result in reduced assay sensitivity or assay failure.

Due to potential differences in assay performance, serial monitoring of a patient's EBV viral load should be performed using the same exact assay.

CPT CODE: 87799

DAY(S) SET UP: Monday through Friday; 7 a.m.-4 p.m. **ANALYTIC TIME**: 2 days

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager or
Rebecca Wortman, MML Laboratory Technologist Resource Coordinator
Telephone: 800-533-1710